Previous close | 249.50 |
Open | 248.50 |
Bid | 249.00 x 50000 |
Ask | 249.50 x 50000 |
Day's range | 248.50 - 248.50 |
52-week range | 210.30 - 260.00 |
Volume | |
Avg. volume | 11 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 08 Nov 2023 - 13 Nov 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
BD's (BDX) slew of product launches raises optimism about the stock.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has been ranked in the top 10 for overall transparency and awarded Best Code of Conduct among S&P 250 companies in the fifth annual U.S. Transparency Awards by Labrador, a global communications firm specializing in corporate disclosures.
BD's (BDX) latest partnership is likely to accelerate the delivery of innovative personalized therapies to patients who need them the most.